All In Biotech

Drug Trial Radar · NCT06221683

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

A Multicenter Clinical Study of Molecular Subtyping Combined With MRD-driven Remission Induction Regimen in Children and Adolescents With AML: A Phase II Cohort Study (GMCAII)

Last checked: Nov 20, 2026Latest source record: Aug 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Jan 1, 2024

Primary completion

Dec 2028

Study completion Dec 2029

Sponsor

Lead sponsor
Children's Hospital of Soochow UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to estimate the rate (probability) of complete remission or complete remission with incomplete count recovery (CR/CRi) with negative MRD after induction I and II, event-free survival (EFS), and cumulative incidence (probability) of relapse (CIR), in patients receiving molecular/precision medicine and MRD-driven remission inductions, and to assess secondarily if there is an improvement over the AML2018 protocol.

Conditions

  • AML, Childhood
  • Acute Myeloid Leukemia

Interventions

  • HomoharringtonineDrug

    3mg/m2/day for weighing \>10kg, 0.1mg/kg/day for weighing ≤10kg, d1-7, ivgtt, qd, more than 6 hours

  • CytarabineDrug

    100mg/m2/q12h for weighing \>10kg, 3.3mg/kg/q12h for weighing ≤10kg, d1-7, ivgtt, q12h, more than 30 minutes in SDC group; 10mg/m2/q12h for weighing \>10kg, 0.33mg/kg/q12h for weighing ≤10kg, d1-10, s.c.,q12h (the first dose at 8 am) in the LDC group;

  • EtoposideDrug

    100mg/m2/d for weighing \>10kg, 3.3mg/kg/d for weighing ≤ 10kg, d1-5, ivgtt, qd, more than 4 hours

  • VenetoclaxDrug

    100mg/m2/d for weighing \>10kg, 3.33mg/kg/d for weighing ≤10kg, d12-25, po, qd

  • Mitoxantrone hydrochloride liposomeDrug

    5mg/m2/d for weighing \>10kg, 0.17mg/kg/d for weighing ≤ 10kg, d1, 3, 5, ivgtt, qod, more than 2 hours at 10 am.

  • Recombinant Human Granulocyte Colony-Stimulating FactorDrug

    5ug/kg/d, d1-10, s.c., qd, at 1pm

  • Idarubicin HydrochlorideDrug

    3mg/m2/day for weighing \>10kg, 0.1mg/kg/day for weighing ≤ 10kg, d1-7, ivgtt, qd, more than 6 hours.

  • SorafenibDrug

    100mg/m2/day for weighing \>10kg, 3.3mg/kg/day for weighing ≤10kg, from identification, po, qd

  • GilteritinibDrug

    20mg/m2/day for weighing \>10kg, 0.7mg/kg/day for weighing ≤ 10kg, from identification, po, qd

  • AvapritinibDrug

    50mg/m2/day for weighing bodyweight \>10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of CR/CRi with negative MRDTime frame: Day 26 (HAE group) and Day 32 (MAG+Ven group) for remission induction 1 and 2 are the necessary time points for response evaluation.
  2. Event-free survivalTime frame: From date of treatment until the date of the occurrence of the event, whichever comes first, assessed up to 72 months. Patients remaining event-free are censored at the last follow-up time.
  3. Cumulative incidence of relapseTime frame: From date of treatment until the date of when a failure of CIR occurs, whichever comes first, assessed up to 72 months.

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Institute of Genomics, Chinese Academy of Sciences

    Beijing, China · Not yet recruiting

  • First Affiliated Hospital Of University of Science and Technology of China

    Hefei, Anhui, China · Not yet recruiting

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China · Not yet recruiting

  • Guangzhou Women and Children Medical Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Not yet recruiting

  • Kaifeng Children's Hospital

    Kaifeng, Henan, China · Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Not yet recruiting

  • Third Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • XiangYa Hospital Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Children's Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • Xuzhou Children's Hospital

    Xuzhou, Jiangsu, China · Not yet recruiting

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China · Not yet recruiting

  • Children's Hospital Of Fudan University

    Shanghai, Shanghai Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.